Multiple Sclerosis, Lower Urinary Tract Symptoms
Conditions
Keywords
magnetic stimulation, multiple sclerosis
Brief summary
This work is intended to assess the effect of repetitive magnetic stimulation on the sacral roots versus repetitive magnetic stimulation on motor cortex in multiple sclerosis patients with the lower urinary tract dysfunction.
Detailed description
Twenty Multiple sclerosis patients with lower urinary tract symptoms will be receiving repetitive magnetic stimulation on sacral roots. Another twenty Multiple sclerosis patient with lower urinary tract symptoms will be receiving repetitive magnetic stimulation on motor cortex. Treatment outcome will be assessed and compared between the two groups. Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses (total duration: 16 minutes) once a day for four consecutive days for two weeks.
Interventions
OTHERmagnetic stimulation
Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks
Sponsors
Cairo University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* Multiple Sclerosis patients (diagnosed by McDonald criteria 2010) with lower urinary tract dysfunction * Adults more than 18 years * Unresponsiveness to medical treatment * Urodynamic diagnosis of detrusor overactivity and/or detrusor underactivity and/or detrusor-sphincter dyssynergia
Exclusion criteria
* Urinary tract infections * Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline King's Health QoL questionnaire score after treatment | 1-7 days after treatment | questionnaire evaluates the impact of lower urinary tract symptoms on patient's quality of life. High scores represent a worse quality of life, with no cut-off values. |
| Change from baseline Post-void residual urine after treatment | 1-7 days after treatment | Measured by ultrasound It is the volume of urine left in the bladder at the completion of micturition Measured in milliliters (mL) |
| Change from baseline Maximum Cystometric Capacity (MCC) after treatment | 1-7 days after treatment | Measured by urodynamic evaluation Measured in millimeters (mL) It is the volume at which the patient states that he/she can no longer delay micturition because of strong desire to void or urgency |
| Change from baseline Maximum Flow Rate (Qmax) after treatment | 1-7 days after treatment | Measured by urodynamic evaluation Measured in milliliters per second (mL/sec) It is the maximum measured value of the flow rate |
| Change from baseline Detrusor pressure at maximum flow rate (Pdet @Qmax) after treatment | 1-7 days after treatment | Measured by urodynamic evaluation Measured in centimeter water (cmH2O) It represents the effect of the active and/or passive forces generated by the detrusor muscle |
Outcome results
None listed